Raymond C. Bergan, M.D. is an internationally regarded cancer specialist known for leading breakthrough studies on how cancer cells spread and preventive treatments for high-risk patients.
Dr. Bergan was previously director of experimental therapeutics for Northwestern University's Robert H. Lurie Cancer Center, co-director of the Center for Molecular Innovation and Drug Discovery as well as a professor in the Department of Medicine. His laboratory at Northwestern conducted groundbreaking research to expand the understanding of how early-stage cancer transforms to eventually move throughout the body. He developed and leads one of only five National Cancer Institute-funded phase I cancer chemoprevention clinical trials groups.
At the OHSU Knight Cancer Institute, Dr. Bergan has established a research laboratory to continue this work bringing targeted therapies to advanced stage prostate cancer patients. His other priorities will include expanding the institute's offering of phase I drug trials and applying the latest drug developments. His goal is to work with the OHSU Knight Cancer Institute's team of researchers to provide highly tailored treatments to patients, including those with early or advanced cancer, and, ultimately change the course of their disease.
Memberships and Associations
American Association for the Advancement of Science
American Association for Cancer Research (12120)
American Society of Clinical Oncology
Associate American College of Physicians
Eastern Cooperative Oncology Group
Illinois Medical Society
National Cancer Institute Antisense Interest Group
Oregon Medical Society
Zacchaeus Medical Clinic Advisory Committee